Bringing new safety-critical medical devices to market faces several major challenges, but modeling and formal methods can facilitate this process from early system requirements verification to platform-level testing to late-stage clinical trials.
M
edical devices play an essential role in patient care around the world. Some devices, such as those that manage heart rhythm, can be lifesaving. For example, an estimated 800,000 people in the US have an implanted defibrillator, with 10,000 added monthly. Clinical trials show that such defibrillators reduce mortality from cardiac arrest by 31 percent. 1 The global market for medical devices exceeded $289 billion in 2012. 2 Example devices range in complexity from drug-infusion pumps to surgical robots to deepbrain stimulation systems. These critical technologies combine hardware and software, each of which must be rigorously verified to be efficacious and safe.
According to the US Food and Drug Administration, 15 percent of all medical device recalls from 2008 to 2012 were caused by software-related issues, 3 and this figure is expected to rise as devices become more intricate. For example, software in pacemakers and defibrillators contain 80,000−100,000 lines of code to automate sensing, control, and actuation decisions within the human body over the devices' five-to-seven-year lifetime. 4 A key challenge for medical device manufacturers is developing high-confidence software that will guarantee that the device remains effective and never endangers patients. This is especially difficult in implantable devices given the underlying physiology's complexity and great variability among patients. Currently, these devices can only be evaluated when connected to the organs they affect, at the clinical trial stage just before going to market. However, the advent of computer models of various physiological processes now enables early model-based verification.
Focusing on implantable cardiac devices, we explore emerging physiological modeling techniques and how formal methods in particular can assess device safety and efficacy throughout the entire development and certification process.
HUMAN-IN-THE-LOOP MEDICAL DEVICES
Medical devices can be broadly classified as closed-or open-loop.
As Figure 1 shows, a closed-loop device such as a pacemaker is in a feedback loop with the organ(s) it affects: the device monitors certain physiological variables like heart rate and delivers therapy, in the form of low-energy electrical pulses, to maintain a healthy heart rate. Another example of a closedloop device under development is the artificial pancreas, which monitors blood-glucose levels and delivers insulin to maintain safe glucose levels. 5 In contrast, an open-loop device either monitors physiological variables or delivers therapy, but not both. For example, a drug-infusion pump delivers preprogrammed and nonreactive therapy but does not measure any physiological variables, whereas a blood-pressure monitor measures physiological signals but does not deliver therapy.
Open-loop devices must be operated by professionals to ensure patient safety. Closed-loop devices largely operate autonomously and thus require very little physician intervention, permitting a more independent lifestyle for the patient. The continuous monitoring of physiological variables and timely delivery of therapy necessitate moving most closed-loop device functionality to the software. Because this software is life-critical, verification methods must provide a high confidence in its correctness.
MODEL-BASED VALIDATION OF CLOSED-LOOP DEVICES
The advent of computer models of physiological functions, such as those developed by the University of Washington's Physiome Project (http:// nsr.bioeng.washington.edu), enable model-based design (MBD) of closedloop medical devices that leverage efficient complementary approaches drawn from various engineering and computer science disciplines. In MBD, the device, or a model of the device, is connected to a model of the controlled physiology it interacts with. High confidence validation is achieved when, after considering all of the physiological model's possible behaviors, the device does not adversely affect the connected organ.
Modeling human physiology is very different from modeling humanmade systems. Physiology is much more complex and less well understood than even intricate machines like cars and airplanes, and its scale spans from the molecular to the entire body. In addition, variability among humans is significantly greater than that among machines coming off an assembly line. These differences make model-based validation of closed-loop devices difficult.
Consider, for example, modelbased validation of the cardiac pacemaker, in which the heart is the organ to be modeled.
The heart is a specialized muscle that pumps oxygenated blood to the rest of the body. It is composed of four chambers-two upper chambers called the left and right atria, and two lower chambers called the left and right ventricles-that contract synchronously. A healthy adult's resting heart rate is 60 to 100 beats per minute (each ventricular contraction is a beat). The heart's contractions are controlled by waves of spontaneous electrical depolarization Pacemaker operating in a closed loop with the heart. The atrial and ventricular leads sense electrical activity inside the heart tissue and actuate the organ to maintain a desired heart rate. AP: atrial pacing event; AS: atrial sensing event; VS: ventricular sensing event.
that originate in the sino-atrial (SA) node of the right atrium and propagate first throughout both atria, causing them to contract, and then down to the ventricles along well-defined conduction pathways, causing the ventricles to contract in turn. The SA node is thus referred to as the heart's natural pacemaker.
Under certain disease states, the heart rate drops below what is needed to maintain adequate blood flow to the body-a condition known as bradycardia. When this is due to abnormalities in the heart's electrical conduction system, a pacemaker might be recommended as treatment. The device is implanted near the patient's left collar, as shown in Figure 1 , and has two leads: one connected to the right atrium, and the other to the right ventricle.
The leads function both as sensors and effectors: if either does not sense electrical activity within certain time limits, indicating a delayed or missed contraction, the device will send an electric pulse to the corresponding chamber to provoke contraction, thus acting as an artificial pacemaker. The complex algorithms for detecting missed beats are implemented in software that runs within the device. Part of the difficulty of performing that detection comes from the great variability in heart rates among patients and even within a single patient across time. Moreover, because the pacemaker is limited to sensing electrical activity through its two leads, different phenomena can manifest themselves identically to the device, complicating detection.
In some circumstances, the pacemaker can induce inappropriately elevated heart rates, or tachycardia, which would not have occurred had the heart been operating on its own. No amount of open-loop device testing and verification can predict this adverse condition, known as pacemaker-mediated tachycardia, which results from the device's interaction with the heart. Hence, there is a need for closed-loop validation of pacemakers as well as for physiological heart models that enable early and rigorous validation.
CHOOSING THE RIGHT PHYSIOLOGICAL MODEL
Researchers have developed different heart models for a range of applications. Figure 2 shows four models that emphasize the cellular, anatomical, electromechanical (EM), and electrophysiological (EP) mechanisms of cardiac function. Several of these models employ more than 4 million finite elements or 100,000 ordinary differential equations to describe the dynamics and take several hours to simulate a single cardiac cycle.
Cellular models describe the generation and spread of electrical activities at the molecular-cellular level. 6 The flow of charged ions into and out of the cardiac cell is responsible for the change in voltage across the cell membrane, and such models reveal how activity across ion channels affects the electrical and mechanical behaviors of heart tissue as well as the impact of drug therapies on ion channels' properties.
Anatomical models are developed using MRI and other imaging technologies and seek to re-create detailed anatomical structures, such as fiber orientations and scar tissue, which impact muscle contraction and the speed and paths of electrical conduction throughout the heart. These models provide a foundation for whole-heart modeling efforts and are also used to simulate the effects of medical devices like stents and artificial valves.
EM models employ partial differential equations (PDEs) to approximate electrical activity in the whole heart based on the structures obtained from anatomical models. Researchers have used EM models to study the mechanical effects of abnormal cardiac rhythms, or arrhythmias, on blood flow, predict the onset of arrhythmias, and evaluate potential therapies. 7 EP models help determine the timing properties of the generation and propagation of electrical signals in a patient's heart, and are based on clinical analysis of the heart rhythm across the myocardium. Clinical EP techniques are commonly used to diagnose arrhythmias: a physician inserts catheters with electrodes into the patient's heart through the veins and measures electrical activity around the electrodes to detect abnormal timing patterns. To assess pacemaker software, which only considers event timing in two heart locations, University of Pennsylvania researchers developed an EP model using timed automata to model the timing for the generation and propagation of electrical signals throughout the heart. As Figure  shows , node automata model signal generation, blocking, and transmission in structures like the atrioventricular (AV) node while path automata model variable conduction delays between node automata. A large number of heart conditions can be modeled via a network of node and path automata with di erent topologies and parameters. Moreover, pacing applied to the heart can be represented as an external activation signal to the node automata.
In addition to the four models shown in Figure , data-driven models t fractional PDEs directly to measured heart rates without modeling the underlying mechanisms, and are used to optimize control of implantable cardiac devices.
CLOSED LOOP MODEL CHECKING OF DEVICE SOFTWARE
Short of clinical trials, current validation practice for closed-loop medical devices focuses on open-loop testing and reviews of the design process. This involves feeding a set of input sequences to the device and then checking the device's output for correctness, typically by comparing it to a prede ned expected output. However, specifying a test case including the input sequence and expected output requires accurately predicting the physiological response to the device's output, which is di cult to do manually and can potentially miss requirements violations, especially for longer test cases. Physiological models-say, a high-delity EM model of the heartcapture these complex dynamics and can generate relevant input sequences in response to the device's output.
Timed automata−based EP heart models are amenable to model checking, a technique that mathematically explores all possible executions of the heart model and device software against speci ed requirements-for example, the pacemaker will always maintain the heart rate above a certain rate limit. Model checking is widely used in the semiconductor industry to verify chip designs at various levels of abstraction, in particular at the register transfer level. The model checker returns requirements violations as an execution trace, which can be analyzed to improve the device software. To capture variability in the heart's behavior (more generally, in the physiological phenomena of interest), the heart model is nondeterministic: for example, rather than specifying that conduction delay in the AV node is always . second, it can be any value in the correct physiological range of [ . , . ] second. The model checker will symbolically explore all executions corresponding to all values in this range, rather than select a few, in search of requirements violations.
Subtle errors in the design of safetycritical systems that often elude conventional simulation and testing techniques can be (and have been) found in this way. Because it is cost-e ective and integrates well with conventional design methods, model checking has been adopted as a standard procedure for the quality assurance of automotive and avionics systems, but has yet to enter the world of medical devices.
Endless-loop tachycardia (ELT) is one example of a safety hazard that arises in the interaction between pacemaker and heart, as shown in Figure . ELT starts with a premature ventricular contraction (PVC), which is a common scenario even in a healthy person. The electrical signal travels from the ventricle to the atrium, triggering an atrial sensing event (AS)-that is, the pacemaker senses an event in the right atrium. As a result, the pacemaker paces the ventricle (VP) after a preprogrammed atrioventricular interval (AVI), triggering ventricle-to-atrium conduction again, and this VP ® AS ® VP positive feedback loop persists. The ventricular rate during ELT is determined by the conduction delay from the ventricle to the atrium and the
FIGURE .
Modeling the timing of electrical behaviors in the heart using a network of ( ) node and ( ) path automata. Each circle is a node automaton that models the generation, blocking, and transmission of electrical events in select heart tissue, and each line is a path automaton that models variable conduction delays between nodes.
programmed delay in the pacemaker, which is very fast.
The healthy condition in Figure 4 demonstrates the same input-output sequence as ELT. In this case, the pacemaker paces the ventricle after each AS generated by the SA node (in contrast to an AS conducted from the ventricle, as in ELT). This is correct pacing at an appropriate and relatively much slower rate than ELT, and consequently maintains adequate blood flow. Failing to distinguish these two conditions in the heart model could introduce false positives when checking for ELT-that is, return the healthy case as evidence for ELT.
PHYSIOLOGICAL MODEL ABSTRACTION AND REFINEMENT
From the example above, we can see that to perform model checking on the closed-loop system the heart model should not only cover all possible inputs to the pacemaker specified in the requirements, it should also have enough details to resolve ambiguous executions that might introduce false positives and/or false negatives. These conflicting requirements cannot be achieved with a single model.
The left side of Figure 5 shows a collection of models of different heart conditions. Because the models do not FIGURE 4. Endless-loop tachycardia (ELT) with backward conduction (yellow arrows) and healthy heart conduction (green arrows) mapped to the same input-output execution of the pacemaker (middle sequence). The heart model should have the details to resolve this ambiguity.
FIGURE 5
. Abstraction and refinement of existing heart models to cover more heart conditions targeted by pacemaker operation while ensuring that new conditions are physiologically valid. Systematically applying abstraction rules (R1−R7) produces an abstraction tree. The root of the tree, heart model H all , covers all possible pacemaker inputs but cannot distinguish the ELT condition from the healthy condition due to the lack of representation of ventricle-to-atrium conduction. Heart model H cond does model this condition and is thus the appropriate choice to model ELT. cover all possible conditions, model checking the pacemaker model with each heart model will not guarantee the device's absolute safety. We thus define abstraction rules (R1−R7) to add behaviors to the original heart models while guaranteeing that the new behaviors are physiologically valid. For example, abstraction rule R4 merges parameter ranges for heart models with the same node and path topologies. Imagine that two node automata N1 and N2 can self-acti- Systematically applying the abstraction rules on the initial set of heart models produces the model abstraction tree shown on the right side of Figure  5 . The root of the tree is a heart model H all with only two node automata producing two-channel inputs to the pacemaker. By allowing both node automata to send inputs to the pacemaker [0, ∞] second after the last input, the heart model H all covers all possible inputs to the pacemaker. However, H all cannot distinguish the ELT condition from the healthy condition due to the lack of representation of ventricle-to-atrium conduction. The heart model H cond models the electrical conduction between the atria and the ventricles with a path automaton and thus is the appropriate model to evaluate ELT. Finally, re-running abstract execution traces (obtained on models closer to the root of the tree) on more concrete heart models (closer to the leaves of the tree) yields clinical interpretations of the abstract results of the model-checking process for physicians. Figure 6 outlines the framework developed at the University of Pennsylvania to implement and test implantable pacemaker designs, which are created using the now commercially available UPPAAL tool environment (www .uppaal.org) developed by researchers at Uppsala University in Sweden and Aalberg University in Denmark.
FROM VERIFIED MODELS TO VERIFIED CODE
During model checking, the abstract UPPAAL model of the pacemaker and heart models are verified against safety requirements.
Using the UPP2SF model translation tool, the models are then automatically synthesized into Stateflow models in the Simulink environment and into code implementations. 11 Each automaton in a network of timed automata is mapped to a parallel parent state in the Stateflow model, and each location in the automaton is mapped to an exclusive state within the parent state. Along with mapping all the edges in the UPPAAL models to the Stateflow models, the behaviors of the Stateflow models are a subset of their corresponding UPPAAL models, thus properties verified in the UPPAAL models still hold in the Stateflow models. Automatic synthesis provides rigorous traceability throughout the development process and ensures that the verified models are correctly translated into verified code.
Finally, the heart models are synthesized into a "heart-on-a-chip" design that can be used to perform closed-loop testing of device implementations.
MODEL-BASED CLINICAL TRIALS
The final step before introducing a new high-risk medical device to market is the clinical trial. The randomized controlled trial (RCT) is the gold standard for guaranteeing that a medical intervention is safe and efficacious. 12 RCTs typically involve multiple stakeholders-including patients, medical investigators, biostatisticians, ethics boards, regulators, and companiesand can cost several millions of dollars and run from four to six years. Nevertheless, technical errors can arise at almost every step of the trial, jeopardizing the results' validity. Even if the trial is well-planned, poor execution, unexpected events, or even pure chance can lead to the wrong conclusions. The application of computer models to the medical domain has largely centered on the design and verification of particular devices, but such • Hardware implementation of veri ed models • Heart-on-a-chip platform FIGURE 6. University of Pennsylvania framework for designing and testing implantable pacemaker designs. Heart models are available at all levels of the framework. models can also assist in the planning and operation of RCTs.
Suppose a medical device manufacturer is designing a new implantable defibrillator to treat certain arrhythmias. Company researchers have validated the hardware and software specifications; they also have successfully implanted and tested the device on animals. To observe the defibrillator's effect on humans, they conduct an RCT that compares the device's efficacy and safety on two groups of patients: a treatment group implanted with the new device, and a control group receiving standard medical care from one or more devices already on the market. The researchers monitor both groups for a predetermined amount of time, after which they evaluate the rate of treated arrhythmias in each group. They analyze the results to determine whether the difference in rates between the groups, if any, is significant-that is, unlikely to be due to chance alone.
As Figure 7 shows, the researchers could design a model-based clinical trial (MBCT) to test numerous assumptions before the RCT starts. They initially model the physiological phenomenon of interest, in this case the spread of electrical activity in the human heart. The model should be valid (not produce too many nonphysiological signals), of course. For an MBCT, the model must also be rich: it should be capable of simulating a large variety of arrhythmias targeted by the new defibrillator. Once such a parameterized model is created, the researchers can generate a large number of model instances by sampling the parameter space from appropriate distributions, which can be inferred from previous trials' data. These model instances constitute the synthetic cohort.
Researchers can use this cohort to analyze the device's effects in ways not possible or practical with an RCT to guide trial protocol design. For example, they can vary the distribution of arrhythmias in the cohort and analyze the resulting impact on device performance. This is equivalent to running multiple trials on different populations in which the arrhythmias appear in different proportions. RCT investigators can then use these results to confirm or revise their confidence in the device's superiority to standard medical care across populations.
RCT investigators can also study the MBCT results' sensitivity to device settings: running the MBCT multiple times with the same synthetic cohort but various device settings will produce solid estimates for how these settings affect the MBCT's outcome. This in turn can inform the investigators whether they need to correct for different settings when designing the trial protocol and analyzing the results. Further, by breaking down the MBCT results by arrhythmia (or other interesting criteria), the investigators can make informed decisions, before the RCT begins, on which classes of arrhythmias are most or least susceptible to treatment by the device. This will help refine the eligibility criteria and focus the trial's efforts on certain classes of patients.
B
ringing new safety-critical medical devices to market faces several major challenges, but modeling and formal methods that draw on expertise in multiple disciplines including computer science, statistics, and medicine can facilitate this process from early system requirements verification to platform-level testing to late-stage clinical trials.
One challenge is the complexity of the physiological phenomena that these devices aim to control. This complexity stems partially from the multiscale nature of human organ operation, which is affected by both molecular factors and patient lifestyle. Another challenge is the devices' limited ability to observe such phenomena, which often can only be improved through increasingly invasive and risky surgical procedures. Coupled together, these challenges imply that the devices' detection and therapy algorithms must safely and reliably deal with considerable uncertainty. By explicitly allowing for nondeterminism in the systems they study, formal methods are well-suited for dealing with this uncertainty. Appropriate physiological models and abstractionand-refinement frameworks must be developed to address the complexity and limited observability of physiological phenomena; abstraction trees take a step in this direction in the domain of electrophysiology. Variability is a third major challenge: how can investigators verify that a device works well in a population of patients who differ greatly in characteristics and medical history? Clinical trials remain the standard and legally accepted way to answer that question. Although models cannot substitute for observations of human patients, MBCTs can alleviate the burden of conducting trials by providing fast, early, and rigorous testing of assumptions. 
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